Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis
source: pixabay.com

Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis

In late January 2024, the U.S. Food and Drug Administration approved a label expansion for Dupixent (dupilumab). Dupixent, a monoclonal antibody targeting IL-4 and IL-13, is currently used to treat…

Continue Reading Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis
Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 2)
Dr. Evan Dellon

Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 2)

Before you read on, make sure you've checked out Part 1 of our interview, where we discussed what eosinophilic esophagitis is, its symptoms and diagnostic criteria, and why Dr. Dellon chose to…

Continue Reading Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 2)
Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 1)
Dr. Evan Dellon

Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 1)

The U.S. Food and Drug Administration (FDA) approved Dupixent for the treatment of moderate-to-severe atopic dermatitis in patients aged 6 months+; the drug is also approved as add-on maintenance therapy…

Continue Reading Expanding Eosinophilic Esophagitis Research: An Interview with Dr. Evan Dellon (Pt. 1)
The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
source: pixabay.com

The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment

According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…

Continue Reading The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment